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Abstract
Background: Transient ischemic attack (TIA) or minor ischemic stroke represents the largest group of cerebrovascular
disease, and those patients have a high risk of early recurrent stroke. Over decades, anticoagulation therapy has been
used prudently in them for likely increasing the risk of intra-/extra-cranial hemorrhagic complications. However,
recently rivaroxaban, a new oral anticoagulant, is proved to be as effective as traditional anticoagulants, while carrying
significantly less risk of intracranial hemorrhage. Therefore, we assumed that patients may benefit from rivaroxaban if
treated soon after TIA or minor stroke, and designed this adequately powered randomized study, TRACE.
Methods and design: The Treatment of Rivaroxaban versus Aspirin in Non-disabling Cerebrovascular Events (TRACE)
study is a randomized, double-blind clinical trial with a target enrollment of 4400 patients. A 14-days regimen of
rivaroxaban 10 mg daily or a 14-days regimen of aspirin 100 mg daily will be administrated to randomized
participants with acute TIA or minor stroke, defined as National Institute of Health Stroke Scale scores ≤3. The primary
efficacy end point is percentage of patients with any stroke (ischemic or hemorrhage) at 14 days. Study visits will be
performed at the day of randomization, day 14 and day 90.
Discussion: Even though the new oral anticoagulants seem to be both safe and effective, few clinical trials have
been carried out to test their effect on non-disabling cerebrovascular events. Treatment with rivaroxaban may
prevent more cerebrovascular events with an acceptable risk profile after TIA or minor stroke, compared with aspirin,
thus helping to improve the outcome of the disease.
Trial registration: No. NCT01923818
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Background
Transient ischemic attack (TIA) and acute minor ische-
mic stroke (MIS), defined as a National Institutes of
Health Stroke Scale (NIHSS) score ≤3 [1], represent the
largest group of patients with cerebrovascular disease. A
total of 150,000 suspected TIAs and MIS are referred to
secondary care for assessment and investigation in
England alone each year [2], and approximately 300,000
TIAs are diagnosed each year in the United States [3].
Though TIA and MIS have commonly been referred
as non-disabling cerebrovascular events, they often
prognosticated a high risk of recurrent disabling stroke.
Previous studies reported that [4, 5] the risks of subse-
quent stroke were as high as 10.5–18.5 % at 90 days after
TIA or MIS, over a half of which occurred in the first
week. Some even believed that the recurrent stroke risk
was likely to be much higher than commonly thought,
about one third patients with ischemic stroke have had
an earlier TIA or MIS [6].
Thrombylisis therapy, antiplatelet therapy and anti-
coagulant therapy play important roles in treatments
of ischemic cerebrovascular disease. Intravenous tissue
plasminogen activator (t-PA) was identified as the only
pharmacological treatment for acute ischemic stroke
approved by the US FDA in 1996 [7], however, it
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usually excluded the MIS patients [8]. About one third
of those, who hadn’t accepted intravenous t-PA treat-
ment since stroke symptoms were mild on hospital
arrival, would have a poor final stroke outcome [9, 10].
For long time, aspirin has been considered as the
standard antiplatelet therapy for ischemic cerebrovascu-
lar diseases. Two large clinical trials indicated that over
2–4 weeks treatment with aspirin after acute ischemic
stroke reduced the risk of recurrent ischemic stroke by
30 % with a small increase in intracranial hemorrhage
[11, 12]. Previous trials [13, 14] on secondary prevention
of noncardiogenic ischemic stroke had reported a combin-
ation of clopidogrel and aspirin had no further benefit
compared with aspirin only. However recently, CHANCE
study [15] excitingly reported that, not associated with
increased hemorrhage events as compared with aspirin
monotherapy, dual antiplatelet therapy (clopidogrel and
aspirin) reduced the risk of recurrent stroke in patients
with TIA and acute MIS. The results shed a light on
exploiting possibly more effective medical therapy for
patients suffered non-disabling cerebrovascular diseases.
Over 50 years, anticoagulants have been used to treat
patients with acute ischemic stroke for preventing early
recurrent stroke and improving neurological outcomes
with the cited reasons including: (1) to halt neurological
worsening; (2) to prevent early recurrent embolization;
(3) to improve neurological outcomes. Although, trad-
itional anticoagulant has showed effectiveness of recurrent
stroke prevention, its use was very limited in patients with
ischemic cerebrovascular events because of higher inci-
dence of bleeding events [16–19]. Proper treatment for
non-disabling cerebrovascular events should be effective,
as well as safe and convenient. Recently, new oral antico-
agulants have received extensive attentions because of the
following advantages, 1) directly targeting the coagulation
cascade with rapid onset/offset of action; 2) fewer side
effects (especially lower rates of major hemorrhage);
3) lower risks for drug-drug interactions; 4) more pre-
dictable responses [20]. One of the new anticoagu-
lants, rivaroxaban, a direct factor Xa inhibitor, has been
approved in US for prevention of deep-vein thrombosis
(DVT) and venous thromboembolism (VTE) in surgery
and for prophylaxis of the risk of stroke in people with
abnormal heart rhythm (non-valvular atrial fibrillation) at
2011, and for treatment of DVT and pulmonary embolism
at 2012. Recent published trials [21, 22] confirmed that
rivaroxaban reduced the mortality of severe cardiovascular
events and improved outcome with less fatal bleeding in
the patients with atrial fibrillation and in the secondary
prevention of patients with acute coronary syndrome.
Moreover, rivaroxaban showed the best cost-effectiveness
of stroke prevention in patients with nonvalvular atrial
fibrillation within the 3 novel oral anticoagulants, i.e.
apixaban, dabigatran and rivaroxaban [23].
Till now, no specific acute therapy is available for the
vast majority of patients with acute non-disabling cerebro-
vascular events other than antiplatelet therapy [15]. This
new anticoagulant agent, rivaroxaban could be a more
effective, as well as safe and convenient option. Therefore,
in this study we will enroll Chinese patients with TIA and
acute MIS, who would show particularly high risk for
recurrent ischemia, low risk for hemorrhage and relatively
stable systematic conditions after cerebrovascular events
onset. And they will be randomly treated with rivaroxaban
(10 mg daily) or aspirin (100 mg daily) to assess the safety
and efficacy of the new medication.
Study objective
The Treatment of Rivaroxaban versus Aspirin in Non-
disabling Cerebrovascular Events (TRACE) study (www.
clinicaltrials.gov identifier NCT01923818) is a random-
ized, double-blind, multicenter, controlled clinical trial
in 4400 Chinese patients with acute TIA or minor stroke.
The primary objective of this trial is to determine
whether rivaroxaban is safe, when added to standard
care, and can reduce the risk of any stroke (both ischemic
and hemorrhagic) when initiated within 24 h of symptom
onset in high-risk patients with TIA or MIS.
Study participants
Totally 4400 patients will be recruited through 60 emer-
gency departments of general hospitals in China. Two
subtypes of patients would be enrolled: I, acute non-
disabling ischemic stroke (<24 h of symptoms onset); II,
acute TIA (<24 h of symptoms onset). Informed consent
would be supported by a patient (or next to kin) informa-
tion leaflet in Chinese. A consulted meeting would be
developed by a study physician to ensure patients and
their families understand the study procedure and consent
to participation in the trial [24].
All patients would receive standard care based on the
recommendations of AHA/ASA guidelines [25, 26]. For
patients with markedly elevated blood pressure, a rea-
sonable goal would be lowering blood pressure by 15 %
during the first 24 h. After the first several days, the
ideal target blood pressure would be <140/90 mm Hg.
Patients with dyslipidemia would be administrated with
statin therapy according to low-density lipoprotein chol-
esterol level. Those patients already taking statins at the
time of onset of TIA or ischemic stroke would continue
their statin therapy. Patients with diabetes would receive
glycemic control according to plasma glucose level. Pa-
tients would be suggested early mobilization and several
lifestyle modifications, include salt restriction, weight loss,
the consumption of a diet rich in fruits, vegetables, and
low-fat dairy products, regular aerobic physical activity,
smoke quitting and limited alcohol consumption.
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The study has been approved by the Medical Ethical
Reviewing Committee of the Fourth Military Medical
University Medical Center. This clinical trial will be con-
ducted in accordance with the principles laid down by
the 18th World Medical Assembly (Helsinki, 1964) and
all applicable amendments laid down by the World
Medical Assemblies and the International Conference
on Harmonization guidelines for Good Clinical Practice.
Study population
The trial would include (Table 1) male and female
patients ≥18 years of age who have an acute MIS or TIA
and can be treated with intervention medication within
24 h of symptoms onset. Symptom onset is defined by
the “last see normal” principle. The patients could be
enrolled if he/she had an acute MIS with NIHSS ≤3 at
the time of randomization or had a TIA onset caused by
focal brain ischemia with resolution within 24 h of symp-
tom onset and moderate to high risk of stroke recurrence
(ABCD2 score ≥4 at the time of randomization).
Patients would be ineligible for the study if they had a
diagnosis of hemorrhage or other pathology, such as
vascular malformation, tumor, abscess, or other major
non-ischemic brain diseases (e.g., multiple sclerosis), on
baseline computed tomography (CT) brain scanning or
magnetic resonance imaging (MRI) + diffusion weighted
imaging (DWI) brain scanning; had modified Rankin
Scale (mRS) score >2 at randomization (premorbid his-
torical assessment); had NIHSS ≥4 at randomization;
had a clear indication for anticoagulation (presumed
cardiac source of embolus, e.g. atrial fibrillation, pros-
thetic cardiac valves known or suspected endocarditis);
had contraindication to investigational medications;
are currently treated (last dose given within 10 days
before randomization) with heparin therapy or oral anti-
coagulation; had history of intracranial hemorrhage; had
gastrointestinal bleed or major surgery within 3 months;
were planning or likely to undergo revascularization (any
angioplasty or vascular surgery) within the next 3 months;
had TIA or MIS induced by angiography or surgery; had
severe non-cardiovascular comorbidity with life expect-
ancy <3 months; were women of childbearing age not
practicing reliable contraception who did not have a docu-
mented negative pregnancy test result.
Study procedures
Figure 1 shows the trial procedures. Participants with
suspected TIA or MIS would firstly receive head CT to
exclude the intracranial hemorrhage and head MRI +
DWI to confirm the area of infarction. A certified, trained
and licensed physician investigator would be required to
confirm the diagnosis of TIA or MIS and to calculate the
ABCD2 score for subjects with TIA or NIHSS score
for subjects with MIS. Once a standardized, structured
interview was performed, the data would be recorded
in the case report form for each patient. All clinical
data, biological samples and radiological images would
be sent to the central study site where a cerebrovascular
neurologist would review the data. Demographic, medical,
social, and behavioral variables would be determined
along with baseline medications. Anthropometry would
be conducted using standardized equipment calibrated on
a daily basis.
Patients meeting these criteria and offering informed
consent would be randomized into 2 arms:
I Receiving a 100-mg dose of aspirin and placebo
rivaroxaban
II Receiving a 10-mg dose of rivaroxaban and placebo
aspirin
Table 1 Inclusion and exclusion criteria
Inclusion criteria
✧ Adult subjects (male or female ≥18 years old)
✧ Acute nondisabling ischemic stroke (NIHSS ≤3 at the time of
randomization) that can be treated with study drug within 24 h of
symptoms onset. Symptom onset is defined by the “last see normal”
principle
✧ TIA (neurologic deficit attributed to focal brain ischemia, with
resolution of the deficit within 24 h of symptom onset), that can be
treated with investigational medication within 24 h of symptoms
onset. Symptom onset is defined by the “last see normal” principle
✧ Informed consent signed
Exclusion criteria
✧ Diagnosis of hemorrhage or other pathology, such as vascular
malformation, tumor, abscess or other major nonischemic brain
disease, on baseline head CT or MRI scan
✧ mRS score >2 at randomization (premorbid historical assessment)
✧ NIHSS ≥4 at randomization
✧ Clear indication for anticoagulation (atrial fibrillation, mechanical
cardiac valves, deep venous thrombosis, pulmonary embolism or
known hypercoagulable state)
✧ Contraindication to investigational medications
✧ Thrombolysis for ischemic stroke within preceding 7 days
✧ History of intracranial hemorrhage
✧ Current treatment (last dose given within 10 days before
randomization) with heparin therapy or oral anticoagulation
✧ Gastrointestinal bleed or major surgery within 3 months
✧ Planned or likely revascularization (any angioplasty or vascular
surgery) within the next 3 months
✧ TIA or minor stroke induced by angiography or surgery
✧ Severe noncardiovascular comorbidity with life expectancy
<3 months
✧ Women of childbearing age not practicing reliable contraception
who do not have a documented negative pregnancy test result
✧ Severe renal failure, defined as Glomerular Filtration Rate (GFR)
<30 ml/min
✧ Severe hepatic insufficiency (Child-Pugh score B to C)
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Patients would receive certain study medication from
day 1 to day 14. The first dose would be given within
24 h of symptom onset. From day 15 to day 90, all
patients would receive 100-mg dose of aspirin as stand-
ard antiplatelet therapy. Study visits would be performed
on the day of randomization at day 14 and day 90. At
randomization and during follow-up visits, the following
information would be collected: a neurologic evaluation
(mRS and NIHSS); a physical examination, including
measurement of weight (kilogram) and vital signs (su-
pine systolic and diastolic blood pressure, heart rate);
laboratory tests, a neurological dysfunctions assessment,
and concomitant medications and adverse events. For
ensuring the safety of patients during the study, the trial
should be stopped if the probability that rate of intra-
cranial hemorrhage exceeded 5 % or the rate of other
hemorrhagic events is more than 10 %. The progress of
the study would be monitored by the data and safety
monitoring board for ensuring the high standards of
ethics and patient safety.
Study outcomes
The primary efficacy end point is percentage of patients
with any new stroke events (ischemic or hemorrhage),
including fatal stroke, at 14 days.
Secondary outcome measures include,
I Percentage of patients at 14 days and 90 days with
new clinical vascular events (ischemic stroke/
hemorrhagic stroke/TIA/myocardial infarction/
vascular death) as a cluster and evaluated
individually;
II mRS score, dichotomized at percentage with score
0–2 versus score 3–6, at 14 days and 90 days
follow-up;
III Changes in NIHSS scores at 14 days and 90-days
follow-up;
IV Efficacy end point would also be analyzed
stratified by etiologic subtypes (nonintracranial
artery diseases versus intracranial artery diseases),
by time randomization (<12 h versus ≥12 h),
by qualifying event (TIA versus MIS), and by
age (dichotomized at a 5-year cut point closest
to median age).
Safety end points include,
I Moderate to severe bleeding event, according to
the Global Utilization of Streptokinase and Tissue
Plasminogen Activator for occluded Coronary
Arteries definition, including fatal bleeding,
intracranial hemorrhage and other hemorrhagic
events required transfusion of blood, even causing
hemodynamic compromise requiring intervention
at 90 days;
II Total mortality at 14-days follow-up;
III Adverse events/severe adverse events reported by
the investigators in 14-days follow-up.
Fig. 1 Study flowchart
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Randomization, allocation concealment and blinding
Subject numbers would be assigned sequentially as each
patient enters the study. After receiving an informed
consent, patients fulfilling the inclusion criteria would
be randomized by computer-generated random numbers
(Microsoft Excel 2010, Redmond, WA, USA) at statistics
research office, Fourth Military Medical University. A
clinical research associate would make opaque blinded
envelopes (with consecutive numbers) and deliver them
to each participating center. Random allocation would
be performed within 24 h after a patient enrolled. The
block size and treatment-assignment table would not be
available to the researchers until the end of the trial.
The study medication would be stored under the
conditions specified on the label in a locked, safe area of
the pharmacy department to prevent unauthorized ac-
cess. Both the study medication and the placebo would
be indistinguishable; they would be manufactured by the
same company and similar in appearance, organoleptic
characteristics, and presentation.
In the event of emergency, an investigator (HJL) and
a clinical pharmacist (JYY) would decide whether it’s
necessary to unblind the subject’s treatment assignment
using the unblinding envelopes provided to the hospital. If
unblinding was necessary, the investigator must record
the reason for unblinding, as well as the date and time of
the event. In each participating center, an independent
researcher would be assigned to collect the trial paper and
electronic records. In the central trial coordinating office,
an independent research assistant (ZZR) would have ac-
cess to all unblinded data and maintain confidentiality of
patient records.
Statistical considerations
The primary null hypothesis of this trial is as follows: in
patients with TIA or MIS treated with aspirin 100 mg
per day, there would be no difference in 14-days risk of
stroke (ischemic or hemorrhagic) in those treated with a
14-days regimen of rivaroxaban 10 mg per day, when
therapy were initiated within 24 h of symptom onset.
The minimum necessary sample size in the trial is estab-
lished by the requirement to detect the smallest expected
clinically meaningful treatment difference comparing the
treatment with placebo. According to the results of previ-
ous clinical studies [4, 5], we speculated the 14-day risk of
stroke recurrence in the placebo (aspirin) group was about
10 % among TIA or MIS patients treated with aspirin
within 24 h of symptom onset. The results from our
preliminary study were used to calculate the sample size
(unpublished data). A relative risk reduction of 28 %
(relative risk with addition of rivaroxaban is 0.72) was
the smallest difference we would attempt to detect.














With a two-sided 5 % significance level (α) and a 90 %
power (1-β), p1 of 0.10, p2 of 0.072, the minimal sample
size per group was estimated to be 2095 patients. About
4400 participants in total 2 groups was a final estimated
sample size with 5 % dropouts (medication nonadher-
ence). Missing values would be remained missing, and
patients would be censored at their last follow-up assess-
ment (time of clinical event, end of study, or last visit
before loss to follow-up).
All analyses would be intention to treat. In these
analyses we would compare conventional-dose of rivar-
oxaban versus aspirin. Kaplan-Meier estimates of the
cumulative risk of a stroke (ischemic or hemorrhagic)
event during a 14 days’ follow-up, with hazard ratios and
95 % confidence intervals calculated using Cox propor-
tional hazards methods and the log-rank test to evaluate
the treatment effect would be reported. The Chi-square
test of association would be used to compare groups at
baseline as appropriate. Logistic regression would be used
to determine the significance of the results obtained. All
statistics would be two-sided with p <0.05 considered
significant.
Study organization
The progress of the study would be monitored by the Data
and Safety Monitoring Board (DSMB) to ensure the high
standards of ethics and patient safety. The DSMB would
monitor the trial via scheduled and unscheduled reviews,
supervise stopping rules and unmasking, and maintain the
confidentiality of internal discussions and validity of the
reports.
An Executive Committee meeting would be organized
to make major decisions. Quality control inspectors
would be responsible for inspecting the quality of re-
search sites and study data periodically, supervising any
quality problem during the trial, and reporting to the
Executive Committee. The members of the Steering
Committee, including two project directors, would be
members of the Executive Committee and would con-
vene monthly (teleconferences or physical meetings) to
review the status of the trial and available blinded
data; they would take appropriate action regarding the
conduct of the study.
An Adjudication Committee charter including member-
ship, role, and responsibilities would be approved before
the start of the trial by the Adjudication Committee and
the Executive Committee. This committee would be com-
posed of Academic Members, including an independent
statistician, who were not otherwise participating in the
trial.
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Discussion
TIA and MIS have commonly been referred as non-
disabling cerebrovascular events and often portend disab-
ling stroke. Although previous study showed that rapid
assessment and early treatment after a non-disabling cere-
brovascular event resulted in a much lower risk of recur-
rent stroke [25], few established or effective therapies
were used in clinical work. Aspirin is the current standard
antiplatelet therapy to prevent recurrent stroke in patients
with acute cerebrovascular event, but the effect is modest,
and moreover weakened by a small increased risk of intra-
cranial hemorrhage. Traditional anticoagulant, if admi-
nistrated immediately after acute ischemic stroke, could
decrease risk of recurrent stroke compared to patients
untreated or received antiplatelet agent [12, 27]. However,
since increased rate of bleeding complications, the useful-
ness of anticoagulation is still in dispute.
There’re few clinical trials to test the effect of new oral
anticoagulants on non-disabling cerebrovascular events,
even though these agents seem to be safe and effective.
Rivaroxaban (a direct factor Xa inhibitor), one of the
new anticoagulants, has received attention widely. Re-
cently it has been confirmed effective in prevention and
treatment of DVT, VTE and pulmonary embolism, and
showed improved outcome in patients with atrial fibrilla-
tion and with acute coronary syndrome [20–22].
However, effects of rivaroxaban for prevention of the
early recurrent risk after TIA and acute MIS are still
unsettled. Anticoagulant therapy, with the new drug
rivaroxaban, might prevent more cerebrovascular events
with an acceptable risk profile after TIA or MIS com-
pared with mono-antiplatelet therapy, thus would be
helpful to improve the outcome of the disease.
We designed TRACE trial as a randomized, double-
blind, multicenter, controlled clinical trial in China. We
would assess the hypothesis that a 14-days rivaroxaban
regimen followed to aspirin administration is superior to
aspirin alone for the treatment of high-risk patients with
acute nondisabling cerebrovascular event.
Trail status
The trial was registered at Clinicaltrials.org and the
study is open for recruitment.
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